New common variants affecting susceptibility to basal cell carcinoma (original) (raw)

Accession codes

Accessions

NCBI Reference Sequence

References

  1. Stacey, S.N. et al. Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. Nat. Genet. 40, 1313–1318 (2008).
    Article CAS Google Scholar
  2. Epstein, E.H. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer 8, 743–754 (2008).
    Article CAS Google Scholar
  3. Gudbjartsson, D.F. et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat. Genet. 40, 886–891 (2008).
    Article CAS Google Scholar
  4. Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221–227 (2009).
    Article CAS Google Scholar
  5. Guedj, M. et al. Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population. Hum. Mutat. 29, 1154–1160 (2008).
    Article CAS Google Scholar
  6. Fernandez, L.P. et al. SLC45A2: a novel malignant melanoma-associated gene. Hum. Mutat. 29, 1161–1167 (2008).
    Article CAS Google Scholar
  7. Moll, R., Divo, M. & Langbein, L. The human keratins: biology and pathology. Histochem. Cell Biol. 129, 705–733 (2008).
    Article CAS Google Scholar
  8. Sulem, P. et al. Two newly identified genetic determinants of pigmentation in Europeans. Nat. Genet. 40, 835–837 (2008).
    Article CAS Google Scholar
  9. Sulem, P. et al. Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat. Genet. 39, 1443–1452 (2007).
    Article CAS Google Scholar
  10. Uitto, J., Richard, G. & McGrath, J.A. Diseases of epidermal keratins and their linker proteins. Exp. Cell Res. 313, 1995–2009 (2007).
    Article CAS Google Scholar
  11. Chan, Y.M., Yu, Q.C., Fine, J.D. & Fuchs, E. The genetic basis of Weber-Cockayne epidermolysis bullosa simplex. Proc. Natl. Acad. Sci. USA 90, 7414–7418 (1993).
    Article CAS Google Scholar
  12. Kowalewski, C. et al. A novel autosomal partially dominant mutation designated G476D in the keratin 5 gene causing epidermolysis bullosa simplex Weber-Cockayne type: a family study with a genetic twist. Int. J. Mol. Med. 20, 75–78 (2007).
    CAS PubMed Google Scholar
  13. Shurman, D. et al. Epidermolysis Bullosa Simplex with mottled pigmentation: mutation analysis in the first reported Hispanic pedigree with the largest single generation of affected individuals to date. Eur. J. Dermatol. 16, 132–135 (2006).
    CAS PubMed Google Scholar
  14. Kim, W.Y. & Sharpless, N.E. The regulation of INK4/ARF in cancer and aging. Cell 127, 265–275 (2006).
    Article CAS Google Scholar
  15. Pasmant, E. et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 67, 3963–3969 (2007).
    Article CAS Google Scholar
  16. Lin, J., Hocker, T.L., Singh, M. & Tsao, H. Genetics of melanoma predisposition. Br. J. Dermatol. 159, 286–291 (2008).
    Article CAS Google Scholar
  17. Helgadottir, A. et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 1491–1493 (2007).
    Article CAS Google Scholar
  18. Saxena, R. et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316, 1331–1336 (2007).
    Article CAS Google Scholar
  19. Scott, L.J. et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341–1345 (2007).
    Article CAS Google Scholar
  20. Zeggini, E. et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 316, 1336–1341 (2007).
    Article CAS Google Scholar
  21. Steinthorsdottir, V. et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat. Genet. 39, 770–775 (2007).
    Article CAS Google Scholar
  22. Mishmar, D. et al. Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc. Natl. Acad. Sci. USA 95, 8141–8146 (1998).
    Article CAS Google Scholar
  23. Parker-Katiraee, L. et al. Identification of the imprinted KLF14 transcription factor undergoing human-specific accelerated evolution. PLoS Genet. 3, e65 (2007).
    Article Google Scholar
  24. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype imputation. Nat. Genet. 40, 1068–1075 (2008).
    Article CAS Google Scholar
  25. Fabbri, M. et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. USA 104, 15805–15810 (2007).
    Article CAS Google Scholar
  26. Graf, J., Hodgson, R. & van Daal, A. Single nucleotide polymorphisms in the MATP gene are associated with normal human pigmentation variation. Hum. Mutat. 25, 278–284 (2005).
    Article CAS Google Scholar
  27. Han, J. et al. A prospective study of telomere length and the risk of skin cancer. J. Invest. Dermatol. 129, 415–421 (2008).
    Article Google Scholar
  28. Bataille, V. et al. Nevus size and number are associated with telomere length and represent potential markers of a decreased senescence in vivo. Cancer Epidemiol. Biomarkers Prev. 16, 1499–1502 (2007).
    Article CAS Google Scholar
  29. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558 (2002).
    Article Google Scholar
  30. Szeverenyi, I. et al. The Human Intermediate Filament Database: comprehensive information on a gene family involved in many human diseases. Hum. Mutat. 29, 351–360 (2008).
    Article CAS Google Scholar

Download references

Acknowledgements

We thank G.H. Olafsdottir and L. Tryggvadottir of the Icelandic Cancer Registry for assistance with the ascertainment of affected individuals, S. Sveinsdottir for assistance with subject recruitment, and H. Sigurdsson for assistance with the figures. We are grateful to I. Saaf for permission to reproduce a section of the Human Intermediate Filament Database in Supplementary Figure 1. This study was supported in part by the Jubilaumsfonds of the Austrian National Bank (project numbers 11946 and 12161), the Swedish Cancer Society, the Radiumhemmet Research Funds and the Swedish Research Council, the US National Institute of Environmental Health Sciences (T32E007155), the US National Institutes of Health (R01CA082354 and R01CA57494), and a Research Investment Grant of the Radboud University Nijmegen Medical Centre.

Author information

Authors and Affiliations

  1. deCODE genetics, Reykjavik, Iceland
    Simon N Stacey, Patrick Sulem, Gisli Masson, Sigurjon A Gudjonsson, Gudmar Thorleifsson, Margret Jakobsdottir, Asgeir Sigurdsson, Daniel F Gudbjartsson, Julius Gudmundsson, Droplaug N Magnusdottir, Solveig Gretarsdottir, Hilma Holm, Valgerdur Steinthorsdottir, Michael L Frigge, Thorarinn Blondal, Jona Saemundsdottir, Hjördis Bjarnason, Kristleifur Kristjansson, Gyda Bjornsdottir, Jeffrey R Gulcher, Thorunn Rafnar, Unnur Thorsteinsdottir, Augustine Kong & Kari Stefansson
  2. Departments of Dermatology, University of Iceland, Reykjavik, Iceland
    Bardur Sigurgeirsson, Kristin Thorisdottir & Jon H Olafsson
  3. Department of Pathology, University of Iceland, Reykjavik, Iceland
    Kristrun R Benediktsdottir & Jon H Olafsson
  4. Department of Plastic Surgery, Landspitali, University of Iceland, Reykjavik, Iceland
    Kristin Thorisdottir, Rafn Ragnarsson & Jon H Olafsson
  5. Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany
    Dominique Scherer, Kari Hemminki & Rajiv Kumar
  6. National Institute of Environmental Health, Budapest, Hungary
    Peter Rudnai
  7. Environmental Health Centre, Cluj, RO-Cluj-Napoca, Romania
    Eugene Gurzau
  8. State Health Institute, Banska Bystrica, Slovakia
    Kvetoslava Koppova
  9. Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain
    Rafael Botella-Estrada & Eduardo Nagore
  10. Department of Oncology, Instituto Valenciano de Oncologia, Valencia, Spain
    Virtudes Soriano
  11. Division of Dermatology University Hospital, Zaragoza, Spain
    Pablo Juberias, Victoria Fuentelsaz, Cristina Corredera & Matilde Grasa
  12. Health Science Institute, Nanotechnology Institute of Aragon, Zaragoza, Spain
    Berta Saez & José I Mayordomo
  13. Division of Dermatology, San Jorge General Hospital, Huesca, Spain
    Yolanda Gilaberte
  14. Department of Oncology Pathology, Cancer Centre Karolinska, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden
    Veronica Höiom & Johan Hansson
  15. Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
    Annika Lindblom
  16. Department of Surgery, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Johannes J Bonenkamp
  17. Department of Dermatology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Michelle M van Rossum
  18. Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Katja K H Aben & Lambertus A Kiemeney
  19. Comprehensive Cancer Centre IKO, Nijmegen, The Netherlands
    Katja K H Aben & Lambertus A Kiemeney
  20. Department of Public Health, Erasmus Medical Centre, Rotterdam, The Netherlands
    Esther de Vries
  21. Melanoma and Sarcoma Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Mario Santinami & Andrea Maurichi
  22. Department of Immunohematology and Transfusion Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Maria G Di Mauro
  23. Department of Dermatology, Division of General Dermatology, Medical University of Vienna, Vienna, Austria
    Judith Wendt, Pia Hochleitner, Hubert Pehamberger & Ichiro Okamoto
  24. Immunotherapy of Human Tumours Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Licia Rivoltini & Monica Rodolfo
  25. Melanoma Genetics Group, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
    Monica Rodolfo
  26. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Lambertus A Kiemeney
  27. Division of Medical Oncology University Hospital, Zaragoza, Spain
    José I Mayordomo
  28. Department of Community and Family Medicine, Section of Biostatistics and Epidemiology, and the Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Margaret R Karagas
  29. Division of Epidemiology and Community Health, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA
    Heather H Nelson

Authors

  1. Simon N Stacey
  2. Patrick Sulem
  3. Gisli Masson
  4. Sigurjon A Gudjonsson
  5. Gudmar Thorleifsson
  6. Margret Jakobsdottir
  7. Asgeir Sigurdsson
  8. Daniel F Gudbjartsson
  9. Kristrun R Benediktsdottir
  10. Kristin Thorisdottir
  11. Dominique Scherer
  12. Kari Hemminki
  13. Peter Rudnai
  14. Eugene Gurzau
  15. Kvetoslava Koppova
  16. Rafael Botella-Estrada
  17. Virtudes Soriano
  18. Pablo Juberias
  19. Berta Saez
  20. Yolanda Gilaberte
  21. Victoria Fuentelsaz
  22. Cristina Corredera
  23. Matilde Grasa
  24. Veronica Höiom
  25. Annika Lindblom
  26. Johannes J Bonenkamp
  27. Michelle M van Rossum
  28. Katja K H Aben
  29. Esther de Vries
  30. Mario Santinami
  31. Maria G Di Mauro
  32. Andrea Maurichi
  33. Judith Wendt
  34. Pia Hochleitner
  35. Hubert Pehamberger
  36. Julius Gudmundsson
  37. Droplaug N Magnusdottir
  38. Solveig Gretarsdottir
  39. Hilma Holm
  40. Valgerdur Steinthorsdottir
  41. Michael L Frigge
  42. Thorarinn Blondal
  43. Jona Saemundsdottir
  44. Hjördis Bjarnason
  45. Kristleifur Kristjansson
  46. Gyda Bjornsdottir
  47. Ichiro Okamoto
  48. Licia Rivoltini
  49. Monica Rodolfo
  50. Lambertus A Kiemeney
  51. Johan Hansson
  52. Eduardo Nagore
  53. José I Mayordomo
  54. Rajiv Kumar
  55. Margaret R Karagas
  56. Heather H Nelson
  57. Jeffrey R Gulcher
  58. Thorunn Rafnar
  59. Unnur Thorsteinsdottir
  60. Jon H Olafsson
  61. Augustine Kong
  62. Kari Stefansson

Contributions

The study was designed and results were interpreted by S.N.S., P.S., J.R.G., T.R., A.K., J.H.O., U.T. and K.S. Patient ascertainment and recruitment was organized and carried out by S.N.S., B. Sigurgeirsson, K.R.B., K.T., R.R., D.S., K.H., P.R., E.G., K. Koppova, R.B.-E., V. Soriano, P.J., B. Saez, Y.G., V.F., C.C., M.G., V.H., A.L., J.J.B., M.M.v.R., K.K.H.A., E.d.V., M.S., M.G.D.M., A.M., J.W., P.H., H.P., J.G., S.G., H.H., V. Steinthorsdottir, K. Kristjansson, G.B., I.O., L.R., M.R., L.A.K., J.H., E.N., J.I.M., R.K., M.R.K., H.H.N., J.H.O. and U.T. Biological material collection and handling was supervised by S.N.S., D.S., P.R., E.G., K. Koppova, B. Saez, V.H., A.L., K.K.H.A., J.S., H.B., I.O., M.R., M.R.K., H.H.N. and U.T. Genotyping was supervised by S.N.S., M.J., A.S., J.G., D.N.M., S.G., H.H., V. Steinthorsdottir, T.B., T.R. and U.T. Statistical analysis was carried out by P.S., G.T., D.F.G., M.L.F. and A.K. Bioinformatic analysis was carried out by S.N.S., S.A.G. and G.M. Authors S.N.S., P.S., A.K. and K.S. drafted the manuscript. All authors contributed to the final version of the paper. Principal collaborators for the case-control population samples were J.H.O. (Iceland), H.H.N. and M.R.K. (USA), R.K. (Eastern Europe), J.I.M. and E.N. (Spain), J.H. (Sweden), L.A.K. (The Netherlands), M.R. (Italy) and I.O. (Austria).

Corresponding authors

Correspondence toSimon N Stacey or Kari Stefansson.

Ethics declarations

Competing interests

Authors whose affiliations are listed as deCODE Genetics are shareholders and/or employees of deCODE Genetics, a biotechnology company. deCODE Genetics intends to incorporate the variants described in this paper into its genetic testing services.

Supplementary information

Rights and permissions

About this article

Cite this article

Stacey, S., Sulem, P., Masson, G. et al. New common variants affecting susceptibility to basal cell carcinoma.Nat Genet 41, 909–914 (2009). https://doi.org/10.1038/ng.412

Download citation